Everybody loves promising biopharmaceutical news, regardless of whether you’re a shareholder or not; getting news of a promising treatment for a sinister disease is something to laud. However, there’s something very, very sweet about betting on a biopharma outfit with an investment and seeing that holding rocket on news of a breakthrough. Today, investors in…